BioNTech announced that its HER2-targeting antibody-drug conjugate achieved superior results over Roche's Kadcyla in a Phase 3 clinical trial conducted in China involving hard-to-treat breast cancer patients. This pivotal success heightens anticipation for regulatory submissions in China and raises expectations for an ongoing global late-phase study. The trial's positive outcome could reshape treatment landscapes for HER2-positive breast cancers, demonstrating the potency of ADC platforms.